Significant preclinical efficacy in various cancers, including lymphoma, SCLC, and other solid tumors. Although resistance due to Mcl-1 expression and thrombocytopenia posed challenges, combination strategies and dose management provided effective solutions. The gene discussed is MCL1; the disease is small cell lung carcinoma.